Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
Holding ABUS?
Track your performance easily
ABUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.79 - $4.73
Previous Close$3.42
Volume223.66K
Average Volume (3M)1.16M
Market Cap
$648.06M
Enterprise Value$521.71M
Total Cash (Recent Filing)$127.79M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Feb 27, 2025EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding189,491,685
10 Day Avg. Volume976,356
30 Day Avg. Volume1,160,079
Standard Deviation0.27
R-Squared0.14
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.14
Price to Sales (P/S)98.09
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue77.38
Enterprise Value/Gross Profit28.76
Enterprise Value/Ebitda-6.99
Forecast
1Y Price Target
$5.20Price Target Upside52.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Arbutus Biopharma News
PremiumCompany Announcements
Arbutus Biopharma Highlights Hepatitis B Treatment AdvancesBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe IM-PROVE I dataset suggests that a functional cure in HBV is achievable with a finite treatment regimen including imdusiran.
Safety And TolerabilityThe combination of imdusiran and interferon was generally safe and well-tolerated, with no serious adverse events related to the treatment.
Therapeutic AdvancementsThe combination of imdusiran and pegylated interferon alfa-2a achieved undetectable HBsAg levels in a significant number of patients, which supports the potential for a functional cure.
Bears Say
Earnings OutlookThere is no change to the earnings outlook, which might imply stagnation or lack of growth in expected financial performance.
Industry EnvironmentThe chronic hepatitis B treatment space is difficult, as highlighted by major companies withdrawing, which may indicate underlying market challenges.
Market AdoptionThere is a lack of consensus among key opinion leaders on the necessity of reintroducing PEG-IFN into treatment regimens, suggesting potential challenges in market adoption.
---
Ownership Overview
1.90% Insiders
9.78% Mutual Funds
20.14% Other Institutional Investors
58.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABUS FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $1.79 and its highest was $4.72 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Currently, no data Available
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is Feb 27, 2025 which is in 93 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on Nov 06, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.006.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -$0.08.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 189,491,680 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Saba Capital Management. It holds Arbutus Biopharma Corporation’s shares valued at 3M.
---
Arbutus Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.20 (52.05% Upside)
$5.20 (52.05% Upside)
Blogger Sentiment
Bullish
ABUS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 233.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.88%
12-Months-Change
Fundamentals
Return on Equity
-67.81%
Trailing 12-Months
Asset Growth
-11.47%
Trailing 12-Months
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
ABUS Earnings Call
Q4 2024
0:00 / 0:00
---
ABUS Stock 12 Month Forecast
Average Price Target
$5.20
▲(52.05% Upside)
Technical Analysis
Best Analysts Covering ABUS
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+13.89%
reiterated a buy rating 9 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +13.89% per trade.
---